MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of marketable...
$71,065K
Net cash provided by
(used in) investing...
$32,881K
Canceled cashflow
$38,184K
Net increase
(decrease) in cash, cash...
$18,897K
Canceled cashflow
$13,984K
Purchases of marketable
securities
$23,184K
Amounts loaned under
note receivable
$15,000K
Stock-based compensation
expense
$1,362K
Non-cash operating lease
expense
$1,074K
Deposits and other assets
-$940K
Depreciation
$174K
Other long-term
liabilities
$31K
Net cash used in
operating activities
-$13,984K
Canceled cashflow
$3,581K
Net loss
-$11,386K
Accrued expenses and
other current...
-$3,119K
Operating lease
liabilities
-$1,844K
Prepaid expenses and
other current assets
$588K
Accounts payable
-$385K
Net accretion of
discounts on marketable...
$243K
Back
Back
Cash Flow
source: myfinsight.com
Ikena Oncology, Inc. (IKNA)
Ikena Oncology, Inc. (IKNA)